Elixira: Inside the World's First Autonomous Cancer Prevention Platform

Invented and founded by Tess Fries in 2025, Elixira is a breakthrough AI-guided nanomedicine platform designed for autonomous, lifelong cancer prevention across all cancer types. Its feasibility has been independently verified by a leading Contract Research Organization (CRO), and all core technologies underlying Elixira have been peer-reviewed and scientifically validated.

This white paper is the first comprehensive, non-confidential walkthrough of Elixira—the world’s first autonomous cancer-prevention platform. It presents the system’s step-by-step internal logic and frames a new approach to preventive medicine: continuous, closed-loop protection that operates for life without external input, while preserving full protection of sensitive intellectual property.

Designed for scientists, policymakers, partners, and the public, this publication complements previous disclosures on feasibility and scalability, bridging the gap between concept and comprehension. Without revealing any implementation details, it illustrates Elixira’s operational logic: from real-time detection to autonomous elimination, energy harvesting, dormancy, and reactivation—over and over, for life.